Cocrystal pharma to extend phase 2a influenza challenge study with oral pb2 inhibitor cc-42344

Bothell, wash., dec. 31, 2024 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces plans to extend enrollment in the phase 2a human challenge study with its investigational, broad-spectrum, oral influenza pb2 inhibitor cdi-42344 due to unexpectedly low influenza infection among study participants who were challenged with a h3n2 viral strain. this randomized, double-blind, placebo-controlled phase 2a study is evaluating the safety, tolerability, pharmacokinetics (pk), antiviral activity and clinical measurements of cc-42344 at a single site in the united kingdom.
COCP Ratings Summary
COCP Quant Ranking